ALNY:NSD-Alnylam Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 235.56

Change

0.00 (0.00)%

Market Cap

USD 30.38B

Volume

1.76M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Address: 675 West Kendall Street, Cambridge, MA, United States, 02142

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 92.70B
ARGX argenx NV ADR

N/A

USD 35.89B
BGNE BeiGene Ltd

N/A

USD 22.85B
MRNA Moderna Inc

N/A

USD 21.00B
UTHR United Therapeutics Corporatio..

N/A

USD 16.70B
RPRX Royalty Pharma Plc

N/A

USD 15.14B
INCY Incyte Corporation

N/A

USD 14.67B
SMMT Summit Therapeutics PLC

N/A

USD 13.75B
PCVX Vaxcyte Inc

N/A

USD 13.28B

ETFs Containing ALNY

GNOG:LSE Global X Genomics & Biote.. 6.94 % 0.00 %

N/A

USD 8.22M
GN0M:XETRA Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 8.00M
MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 5.05 % 0.00 %

N/A

USD 4.80M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 3.47 % 0.35 %

N/A

USD 0.43B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.62 % 0.00 %

N/A

USD 0.04B
BBP Virtus LifeSci Biotech Pr.. 2.39 % 0.79 %

N/A

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 2.39 % 0.95 %

N/A

USD 0.07B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.29 % 0.00 %

N/A

USD 0.05B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.18 % 0.00 %

N/A

USD 0.05B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

N/A

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

N/A

N/A
TMFX Motley Fool Next Index ET.. 1.97 % 0.00 %

N/A

USD 0.03B
LABU Direxion Daily S&P Biotec.. 1.48 % 1.14 %

N/A

USD 0.99B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

N/A

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

N/A

N/A
IUSZ:SW iShares Edge MSCI USA Siz.. 0.52 % 0.00 %

N/A

N/A
IWSZ:SW iShares Edge MSCI World S.. 0.21 % 0.00 %

N/A

USD 0.29B
ETHO Amplify ETF Trust 0.00 % 0.45 %

N/A

USD 0.18B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

N/A

N/A
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

N/A

CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

N/A

USD 1.19B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 6.55B
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
IUSF:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.29B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.00 % 0.00 %

N/A

USD 0.29B
IWFS:LSE iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.28B
IWSZ:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

USD 0.28B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

USD 0.02B
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

N/A

USD 0.24B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

N/A

USD 4.07M
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

N/A

USD 0.63B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

N/A

USD 0.02B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.07% 76% C+ 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.07% 76% C+ 77% C+
Trailing 12 Months  
Capital Gain 43.87% 75% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.87% 75% C 80% B-
Trailing 5 Years  
Capital Gain 140.54% 87% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 140.54% 87% B+ 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 14.32% 61% D- 68% D+
Dividend Return 14.32% 61% D- 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.47% 89% A- 66% D+
Risk Adjusted Return 52.14% 95% A 79% B-
Market Capitalization 30.38B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.